AVALO THERAPEUTICS INC (AVTX) Forecast, Price Target & Analyst Ratings
NASDAQ:AVTX • US05338F3064
18.36 USD
-0.49 (-2.6%)
At close: Mar 4, 2026
18.36 USD
0 (0%)
After Hours: 3/4/2026, 8:09:25 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AVALO THERAPEUTICS INC (AVTX).
Forecast Snapshot
Consensus Price Target
$36.83
+ 100.62% Upside
Next Earnings Forecast
Release DateMar 18, 2026
PeriodQ4 / 2025
EPS Estimate-$1.49
Revenue Estimate
ChartMill Buy Consensus
86.25%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$36.83
Upside
+ 100.62%
From current price of $18.36 to mean target of $36.83, Based on 16 analyst forecasts
Low
$24.24
Median
$36.72
High
$52.50
Price Target Revisions
1 Month
5.05%
3 Months
7.11%
Price Target Summary
16 analysts have analysed AVTX and the average price target is 36.83 USD. This implies a price increase of 100.62% is expected in the next year compared to the current price of 18.36.
The average price target has been revised upward by 7.11% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.25%
AVTX was analyzed by 16 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about AVTX.
In the previous month the buy percentage consensus was at a similar level.
AVTX was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-02 | Guggenheim | Initiate | Buy |
| 2026-01-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-12-18 | Mizuho | Initiate | Outperform |
| 2025-09-29 | BTIG | Reiterate | Buy -> Buy |
| 2025-09-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-15 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-03-25 | Stifel | Initiate | Buy |
| 2025-03-25 | Jefferies | Initiate | Buy |
| 2025-03-20 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-02-28 | Piper Sandler | Initiate | Overweight |
| 2024-12-19 | BTIG | Initiate | Buy |
| 2024-12-17 | LUCID CAPITAL MARKETS | Initiate | Buy |
| 2024-10-24 | HC Wainwright & Co. | Initiate | Neutral |
| 2024-04-16 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2023-06-27 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2023-06-27 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2023-05-10 | RBC Capital | Maintains | Outperform |
| 2023-02-08 | Jefferies | Downgrade | Hold -> Underperform |
| 2022-03-03 | RBC Capital | Maintains | Outperform |
| 2022-03-03 | Jefferies | Downgrade | Buy -> Hold |
| 2021-09-24 | RBC Capital | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 18, 2026
PeriodQ4 / 2025
EPS Estimate-$1.49
Revenue Estimate
Revenue Q2Q-100.00%
EPS Q2Q81.22%
Number of Analysts12
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-0.20%
EPS (3 Months)
-5.83%
Next Earnings Summary
AVTX is expected to report earnings on 3/18/2026. The consensus EPS estimate for the next earnings is -1.49 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 18.05M 234.26% | 1.924M -89.34% | 441K -77.08% | -100.00% | 6.441M | 93.169M 1,346.50% | 129.61M 39.11% | 294.56M 127.27% | 543.78M 84.61% | ||||
| EBITDA YoY % growth | -37.27M 53.68% | -23.286M 37.52% | -40.702M -74.79% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -37.44M 54.41% | -23.444M 37.38% | -40.871M -74.33% | -71.698M -75.42% | -78.738M -9.82% | -110.915M -40.87% | -108.688M 2.01% | -130.064M -19.67% | -67.376M 48.20% | -67.385M -0.01% | 57.241M 184.95% | 265.63M 364.06% | |
| Operating Margin | -207.42% | -1,218.50% | -9,267.80% | N/A | N/A | N/A | N/A | -2,019.32% | -72.32% | -51.99% | 19.43% | 48.85% | |
| EPS YoY % growth | -1,075.20 55.02% | -488.22 54.59% | -164.27 66.35% | -6.20 96.23% | -5.17 16.69% | -4.19 18.96% | -3.44 17.76% | -4.05 -17.63% | -1.59 60.76% | -2.69 -69.02% | 3.21 219.62% | 6.28 95.56% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.49 81.22% | -1.54 -23.22% | -1.37 28.39% | -1.29 41.13% | -1.22 18.03% |
| Revenue Q2Q % growth | -100.00% | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -19.392M -45.68% | -19.673M -31.15% | -19.13M -0.68% | -19.398M -1.04% | -19.737M -1.78% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
25.45%
EPS Next 5 Year
14.59%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
94.88%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
AVALO THERAPEUTICS INC / AVTX Forecast FAQ
Can you provide the average price target for AVALO THERAPEUTICS INC stock?
16 analysts have analysed AVTX and the average price target is 36.83 USD. This implies a price increase of 100.62% is expected in the next year compared to the current price of 18.36.
When does AVALO THERAPEUTICS INC (AVTX) report earnings?
AVALO THERAPEUTICS INC (AVTX) will report earnings on 2026-03-18, after the market close.
What are the consensus estimates for AVALO THERAPEUTICS INC (AVTX) next earnings?
The consensus EPS estimate for the next earnings of AVALO THERAPEUTICS INC (AVTX) is -1.49 USD and the consensus revenue estimate is 0 USD.
How many analysts have analysed AVALO THERAPEUTICS INC (AVTX)?
The number of analysts covering AVALO THERAPEUTICS INC (AVTX) is 16.